Drug Eruptions

Chapter

Abstract

Cutaneous reactions are the most frequently occurring adverse reactions to drugs. These reactions can range from mild (two-thirds of cases) to life-threatening (one-third of cases) in the hospital setting [1, 2]. Distinguishing a mild versus a life-threatening reaction is challenging, yet critical, in the management of drug allergies. Cutaneous manifestations are frequently the earliest signs of a systemic drug allergy and can provide information on the severity and prognosis of an allergic reaction [3]. Numerous risk factors predispose patients to severe cutaneous drug reactions, including immunosuppression (especially infection with human immunodeficiency virus) [4] or mononucleosis [5], female gender [6], number of drugs being taken, and elderly age [7].

Keywords

Flare Neutropenia Psoriasis Proteinuria Cephalosporin 

References

  1. 1.
    Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol. 2011;71(5): 672–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Bigby M, et al. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Lubart R, et al. A novel explanation for the healing effect of the Er:YAG laser during skin rejuvenation. J Cosmet Laser Ther. 2011;13(1):33–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Battegay M, et al. Rash with amoxycillin-clavulanate therapy in HIV-infected patients. Lancet. 1989;2(8671): 1100.PubMedCrossRefGoogle Scholar
  5. 5.
    Patel BM. Skin rash with infectious mononucleosis and ampicillin. Pediatrics. 1967;40(5):910–1.PubMedGoogle Scholar
  6. 6.
    Naldi L, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol. 1999;48(6):839–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting. Arch Dermatol. 2000;136(7):849–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Thong BY, et al. Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol. 2003;90(3): 342–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Bastuji-Garin S, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Chan HL, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126(1): 43–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Strom BL, et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol. 1991;127(6):831–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Naldi L, et al. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol. 1990;126(8):1103–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Roujeau JC, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol. 1990;126(1):37–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Prendiville JS, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr. 1989;115(6):881–7.PubMedCrossRefGoogle Scholar
  15. 15.
    French LA, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Bologina JL, Jorizzo JL, Rapini R, editors. Urticarias, erythemas, and pupuras. 2nd ed. Philadelphia, PA: Elsevier; 2008.Google Scholar
  16. 16.
    Wolkenstein PE, Roujeau JC, Revuz J. Drug-induced toxic epidermal necrolysis. Clin Dermatol. 1998;16(3): 399–408.PubMedCrossRefGoogle Scholar
  17. 17.
    Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19): 1272–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee A. Drug induced skin reactions. London: Pharmaceutical Press; 2006.Google Scholar
  19. 19.
    Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008;122(5):992–1000.PubMedCrossRefGoogle Scholar
  20. 20.
    Chung WH, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Schopf E, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127(6): 839–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Mockenhaupt M, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol. 2003;30(10): 2234–40.PubMedGoogle Scholar
  23. 23.
    Devi K, et al. Carbamazepine–the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol. 2005;71(5):325–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Mockenhaupt M, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Levi N, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009;123(2): e297–304.PubMedCrossRefGoogle Scholar
  26. 26.
    Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2010;85(2):131–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Lebargy F, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23(12):1237–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Revuz J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Wong KC, Kennedy PJ, Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 1999;40(3):131–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.PubMedCrossRefGoogle Scholar
  31. 31.
    Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med. 2011;39(6):1521–32.PubMedCrossRefGoogle Scholar
  32. 32.
    Bastuji-Garin S, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Garcia-Doval I, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136(3):323–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Oplatek A, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27(1):26–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Dunn K, Edwards-Jones V. The role of acticoat with nanocrystalline silver in the management of burns. Burns. 2004;30 Suppl 1:S1–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Wolf R, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005;23(2): 171–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Brown KM, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25(1):81–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87(3): 206–18.PubMedGoogle Scholar
  39. 39.
    Campione E, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol. 2003;83(6):430–2.PubMedGoogle Scholar
  40. 40.
    Prins C, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139(1):26–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Shortt R, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25(3):246–55.PubMedCrossRefGoogle Scholar
  42. 42.
    Valeyrie-Allanore L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4): 847–53.PubMedCrossRefGoogle Scholar
  43. 43.
    Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am. 2010;94(4):727–42. x.PubMedCrossRefGoogle Scholar
  44. 44.
    Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Kano Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439–44.PubMedCrossRefGoogle Scholar
  46. 46.
    Magina S, et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207(1):33–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Gueudry J, et al. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145(2):157–62.PubMedCrossRefGoogle Scholar
  48. 48.
    Power WJ, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102(11):1669–76.PubMedGoogle Scholar
  49. 49.
    Roujeau JC, et al. Reporting adverse drug reactions. Lancet. 1985;2(8466):1244.PubMedCrossRefGoogle Scholar
  50. 50.
    Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol. 1984;120(6):721–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Wolf R, et al. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification. Clin Dermatol. 2005;23(3):311–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Descamps V, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137(3): 301–4.PubMedGoogle Scholar
  53. 53.
    Fiszenson-Albala F, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149(5):1018–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Clark RA, et al. The vast majority of CLA  +  T cells are resident in normal skin. J Immunol. 2006;176(7): 4431–9.PubMedGoogle Scholar
  55. 55.
    Schaerli P, et al. A skin-selective homing mechanism for human immune surveillance T cells. J Exp Med. 2004;199(9):1265–75.PubMedCrossRefGoogle Scholar
  56. 56.
    Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2(4):301–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Picard D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2(46):46ra62.PubMedCrossRefGoogle Scholar
  58. 58.
    Eshki M, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol. 2009;145(1):67–72.PubMedCrossRefGoogle Scholar
  59. 59.
    Saida S, et al. A case of drug-induced hypersensitivity syndrome-like symptoms following HHV-6 encephalopathy. Allergol Int. 2010;59(1):83–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146(12): 1373–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Gupta A, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther. 1992;51(1):56–67.PubMedCrossRefGoogle Scholar
  62. 62.
    Spanou Z, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006;17(10):2919–27.PubMedCrossRefGoogle Scholar
  63. 63.
    Chung WH, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.PubMedCrossRefGoogle Scholar
  64. 64.
    Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36(1):6–11.PubMedCrossRefGoogle Scholar
  65. 65.
    Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60. quiz 161-2.PubMedGoogle Scholar
  66. 66.
    Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy. 2007;27(10): 1425–39.PubMedCrossRefGoogle Scholar
  67. 67.
    Beltraminelli HS, et al. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol. 2005;152(4):780–3.PubMedCrossRefGoogle Scholar
  68. 68.
    Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol. 2009;9(4): 322–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003;4(8):561–72.PubMedCrossRefGoogle Scholar
  70. 70.
    Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Sidoroff A, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case–control study (EuroSCAR). Br J Dermatol. 2007;157(5):989–96.PubMedCrossRefGoogle Scholar
  72. 72.
    Pirquet SV. Serum sickness. Baltimore: Wilkins; 1951.Google Scholar
  73. 73.
    Lawley TJ, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med. 1984;311(22):1407–13.PubMedCrossRefGoogle Scholar
  74. 74.
    Vincent C, Revillard JP. Antibody response to horse gamma-globulin in recipients of renal allografts: relationship with transplant crises and transplant survival. Transplantation. 1977;24(2):141–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Clark BM, et al. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy. 2006;26(5):705–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Wilson CB, Dixon FJ. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med. 1971;134(3):7–18.PubMedGoogle Scholar
  77. 77.
    King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health. 2003;39(9):677–81.PubMedCrossRefGoogle Scholar
  78. 78.
    Knowles SR, Shear NH. Recognition and management of severe cutaneous drug reactions. Dermatol Clin. 2007;25(2):245–53. viii.PubMedCrossRefGoogle Scholar
  79. 79.
    Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol. 2006;6:3.PubMedCrossRefGoogle Scholar
  80. 80.
    Vial T, et al. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992;26(7–8):910–4.PubMedGoogle Scholar
  81. 81.
    Molldrem JJ, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99(3):699–705.PubMedCrossRefGoogle Scholar
  82. 82.
    Hommes DW, van Deventer SJ. Infliximab therapy in Crohn’s disease: safety issues. Neth J Med. 2003;61(4):100–4.PubMedGoogle Scholar
  83. 83.
    D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001;44(7):1717–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol. 2007;34(2):430–3.PubMedGoogle Scholar
  85. 85.
    Lundquist AL, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl. 2007;13(5):647–50.PubMedCrossRefGoogle Scholar
  86. 86.
    Bielory L, et al. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol. 1985;13(3):411–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Joubert GI, et al. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol. 1999;6(4):197–201.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Department of DermatolgoyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations